Addendum to IMC Submission on Drugs for Rare Diseases
Innovative Medicines Canada provides Health Canada with additional input regarding IMC’s March 2021 consultation submission on drugs for rare diseases.
All Resources
Our resource hub to discover reports, policy papers and other forms of informative content
Filter by
Towards a Value-based and Pan-Canadian Rare Disease Strategy
IMC proposes a value-based, pan-Canadian rare disease strategy, built in collaboration with provinces, patients, clinicians and industry to fill gaps and meet specific needs.
